Aselizumab
Modify Date: 2024-01-16 13:51:38
Aselizumab structure
|
Common Name | Aselizumab | ||
|---|---|---|---|---|
| CAS Number | 395639-53-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AselizumabAselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma[1][2]. |
| Name | Aselizumab |
|---|
| Description | Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma[1][2]. |
|---|---|
| Related Catalog | |
| Target |
L-selectin[1][2] |
| In Vitro | Aselizumab 可与人鼠单克隆 HuDreg-55 轻链二硫化形成二聚体[1]。 Aselizumab (5-500 ng/mL; 25 分钟) 在冷冻淋巴结切片中阻断人淋巴细胞对高内皮小静脉的 L-选择素依赖性粘附[3]。 |
| In Vivo | Aselizumab (10 mg/kg; 静脉注射; 单次剂量) 在恒河猴中显示出 12.0 天的最终消除半衰期[3]。 |
| References |
| No Any Chemical & Physical Properties |